iBio Inc. specializes in the development of precision antibody therapeutics, focusing on innovative solutions for challenging therapeutic targets, particularly in the fields of immuno-oncology and cardiometabolic conditions. The company employs a sophisticated drug discovery platform that integrates artificial intelligence (AI) and patented epitope-engineering technology to enhance the identification and optimization of antibodies. This platform allows iBio to target subdominant epitopes, which are often overlooked in traditional drug discovery methods, thereby increasing the likelihood of developing effective therapeutic antibodies. Their technology stack includes ShieldTx™ for antibody masking, EngageTx™ for bispecific antibody engineering, and the StableHu™ Antibody Optimizer, all designed to improve the safety and developability of their clinical candidates.

iBio's therapeutic pipeline is robust, featuring a range of biologics aimed at treating conditions such as obesity, diabetes, and various cancers. Their programs include innovative candidates like IBIO-101, which targets regulatory T cells in solid tumors, and bispecific antibodies that engage the immune system to combat TROP-2-positive cancers. The company is committed to advancing its pipeline through strategic partnerships and collaborations, leveraging its expertise in AI-driven drug discovery to bring first-in-class and best-in-class molecules to market. By focusing on the development of therapies that address unmet medical needs, iBio aims to improve patient outcomes and contribute to advancements in healthcare.

United States

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

Cancer

Immune System Diseases

iBio Inc.

COVID-19

IBIO-200/201 is a Virus-Like Particle (VLP)&nbsp;
<ul class="font_7">
 <li>SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP</li>
 <li>&nbsp;Antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose so as to resemble the structure of a naturally occurring virus</li>
 <li>More info on <a href="https://d1io3yog0oux5.cloudfront.net/_49a57177d7960b5439db64b12491cb61/ibioinc/db/210/1597/pdf/iBio+Corporate+Deck+%282020.07.17%29.pdf">Slide 20</a></li>
</ul>
Virus-like particles (VLPs) (IBIO 200) or lichenase carrier molecule (“LicKMTM”) (IBIO 201) fused to a coronavirus subunit protein with the goal of producing a safe and effective vaccine for COVID-19 disease
<a href="https://www.ibioinc.com/ibio-provides-update-on-ibio-201-covid-19-vaccine-program/">Source</a>

iBio Inc.

Company Details